<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with lower-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs), usually defined as having an International Prognostic Scoring System score of 1.0 or less, and/or &lt;5% myeloblasts, comprise the majority of newly diagnosed and established <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients and have a survival measured in years </plain></SENT>
<SENT sid="1" pm="."><plain>Most will eventually require therapy for their disease, usually when <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-related symptoms or transfusion requirements accelerate and outweigh potential drug-related toxicities </plain></SENT>
<SENT sid="2" pm="."><plain>The decision of when to initiate therapy is far from straightforward </plain></SENT>
<SENT sid="3" pm="."><plain>Erythropoiesis stimulating agents yield responses in up to 40% of appropriately selected patients, while disease-modifying drugs, including lenalidomide, <z:chebi fb="0" ids="2038">azacitidine</z:chebi>, <z:chebi fb="0" ids="50131">decitabine</z:chebi> and anti-thymocyte globulin, can evoke responses as high as 67% in patient subgroups </plain></SENT>
<SENT sid="4" pm="."><plain>Newer therapies hold the promise of activity in patients who have failed standard regimens </plain></SENT>
</text></document>